Greg Aronin standing with hands crossed

Greg Aronin

MPH, Chief Operating Officer

Greg Aronin is Chief Operating Officer (COO) at 32 Biosciences where he leads the company’s mission to advance microbiome-based diagnostics and therapeutics through strategic execution and operational excellence. Greg is a seasoned executive with over 30 years of experience in corporate strategy, operations, and external affairs within the biotechnology, pharmaceutical, and healthcare industries.

Previously, Greg served as Senior Vice President at Paragon Biosciences, where he played a pivotal role in corporate decision-making, driving growth, enhancing brand strength, and securing product reimbursement. He also led corporate affairs at Marathon Pharmaceuticals, contributing to a successful company exit, and held leadership roles at Johnson & Johnson across its pharmaceutical and medical device sectors.

Greg earned a Master of Public Health from the University of Michigan and a Bachelor of Arts in International Relations from Michigan State University. At 32 Biosciences, he focuses on scaling operations, optimizing resources, and fostering a high-performing team as the company transitions to clinical-stage development.